On March 15, 2023 Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported that it will present new research enabling accurate detection and study of the functional relevance of the novel target PVRIG following correction of the GENCODE gene model, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting on April 14-19, 2023, in Orlando, Florida (Press release, Compugen, MAR 15, 2023, View Source [SID1234628847]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"One of the biggest challenges in bringing new treatments to cancer patients, is understanding the complex disease biology," said Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen. "Single cell technology has revolutionized the study of cell populations, particularly immune cells and has been a key technology used by many scientists involved in cancer immunotherapy research. The research we are presenting at AACR (Free AACR Whitepaper) identified an inaccuracy in the single cell gene model technology. By correcting the GENCODE gene model, the most widely used gene model in single cell analysis platforms, we believe that we are enabling a more accurate detection of PVRIG, thereby facilitating the advancement of worldwide research of this pathway. We believe that this advancement could lead to the development of new cancer immunotherapies. As a leader in the DNAM-1 axis space, targeting both PVRIG and TIGIT pathways, we are focused on proof-of-concept studies in cancer patients treated with the triple combination of our potential first-in-class anti-PVRIG, COM701 our potential best-in-class anti-TIGIT, COM902, and a PD-1 inhibitor, with the goal of maximizing clinical benefit for patients."
Poster details:
Session Date and Time: Tuesday April 18, 2023, 9:00 AM – 12:30 PM ET
Session Category: Bioinformatics / Computational Biology / Systems Biology / Convergent Science
Session Title: Algorithms and Statistical Methods
Poster Title: Gene model correction for PVRIG and TIGIT in single cell sequencing data enables accurate detection and study of its functional relevance
Published Abstract Number: 4292
The abstract is available on Compugen’s website at www.cgen.com